✉news HealthMedicine first seen 1 d ago, last 1 d ago, peak #15
Pirtobrutinib beats standard regimen in untreated CLL trial
Original: Pirtobrutinib improves progression-free survival versus bendamustine plus rituximab in previously untreated CLL/SLL
Pirtobrutinib has shown improved progression-free survival compared with bendamustine plus rituximab in patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The finding suggests the BTK inhibitor may become a new first-line option for blood cancer patients, and oncologists are weighing what it means for existing standard-of-care treatment choices.
Why now: New clinical trial results suggest a better first-line therapy for CLL/SLL patients.
PirtobrutinibBendamustineRituximabCLLSLL
Rank over time, top of the chart is #1. 3 snapshots from 1 d ago to 1 d ago.
Evidence
- Pirtobrutinib improves progression-free survival versus bendamustine plus rituximab in previously untreated CLL/SLL · 2 Minute Medicine
API: https://socialmediatrends-api.osmike.com/v1/trends/4889108